Novo Nordisk increases its H1 operating profit by 12%  

2004.08.12
The Danish healthcare company has published its financial statement for H1 which shows a 12% increase in operating profit to DKK 3.4 billion

Healthcare company Novo Nordisk has published its financial statement for H1 2004 which shows a 12% increase in operating profit to DKK 3.4 billion (USD 544 million). Sales increased by 14% measured in local currencies and by 10% measured in Danish kroner. Sales of insulin analogues rose by 90% measured in local currency, in the US sales more than doubled. For the whole of 2004, Novo Nordisk maintains its expectations for sales growth around 10% and operating profit is expected to grow around 5%. The news is reported by national newspaper Jyllands-Posten and on Novo Nordisk's website.

 

Novo Nordisk is a world leader in diabetes care. The company has the broadest product portfolio in the industry, including advanced products in the area of insulin delivery systems. Novo Nordisk employs 18,800 people in 69 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.

 

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×